- Home
- CANF vs EQ Comparison
CANF vs EQ Comparison
Compare CANF & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- EQ
- Stock Information
- Founded
- CANF 1994
- EQ 2017
- Country
- CANF Israel
- EQ United States
- Employees
- CANF N/A
- EQ N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- EQ Health Care
- Exchange
- CANF Nasdaq
- EQ Nasdaq
- Market Cap
- CANF 13.5M
- EQ 13.1M
- IPO Year
- CANF N/A
- EQ 2018
- Fundamental
- Price
- CANF $0.66
- EQ $0.71
- Analyst Decision
- CANF Strong Buy
- EQ Buy
- Analyst Count
- CANF 2
- EQ 3
- Target Price
- CANF $14.00
- EQ $3.00
- AVG Volume (30 Days)
- CANF 314.0K
- EQ 7.7M
- Earning Date
- CANF 08-29-2025
- EQ 08-11-2025
- Dividend Yield
- CANF N/A
- EQ N/A
- EPS Growth
- CANF N/A
- EQ N/A
- EPS
- CANF N/A
- EQ N/A
- Revenue
- CANF $674,000.00
- EQ $30,406,000.00
- Revenue This Year
- CANF $461.72
- EQ N/A
- Revenue Next Year
- CANF N/A
- EQ N/A
- P/E Ratio
- CANF N/A
- EQ N/A
- Revenue Growth
- CANF N/A
- EQ N/A
- 52 Week Low
- CANF $0.63
- EQ $0.27
- 52 Week High
- CANF $3.24
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- CANF 12.02
- EQ 77.71
- Support Level
- CANF $1.00
- EQ $0.36
- Resistance Level
- CANF $1.05
- EQ $0.47
- Average True Range (ATR)
- CANF 0.05
- EQ 0.12
- MACD
- CANF -0.04
- EQ 0.02
- Stochastic Oscillator
- CANF 5.86
- EQ 36.27
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.